Modus Therapeutics Holding AB (publ) (MODTX.ST)
SEK 1.89
(-5.04%)
SEK 1.89
(-5.04%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -16.4 Million SEK | 9.4% |
| 2022 | -18 Million SEK | 12.97% |
| 2021 | -20.69 Million SEK | -243.69% |
| 2020 | -6.02 Million SEK | 86.18% |
| 2019 | -43.57 Million SEK | 11.23% |
| 2018 | -49.09 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -4.8 Million SEK | -50.74% |
| 2024 Q1 | -3.18 Million SEK | 15.55% |
| 2023 Q1 | 5.8 Million SEK | 163.68% |
| 2023 FY | -16.31 Million SEK | 9.4% |
| 2023 Q4 | -3.77 Million SEK | -53.66% |
| 2023 Q3 | -2.45 Million SEK | 43.73% |
| 2023 Q2 | -4.36 Million SEK | -175.15% |
| 2022 Q3 | -2.82 Million SEK | 5.45% |
| 2022 Q1 | -3.06 Million SEK | 75.06% |
| 2022 Q2 | -2.99 Million SEK | 2.38% |
| 2022 FY | -18 Million SEK | 12.97% |
| 2022 Q4 | -9.12 Million SEK | -222.41% |
| 2021 FY | -20.69 Million SEK | -243.69% |
| 2021 Q1 | -1.42 Million SEK | -40.0% |
| 2021 Q4 | -12.28 Million SEK | -176.69% |
| 2021 Q3 | -4.44 Million SEK | -75.33% |
| 2021 Q2 | -2.53 Million SEK | -77.38% |
| 2020 Q4 | -1.02 Million SEK | -46.76% |
| 2020 Q1 | -2.6 Million SEK | 0.0% |
| 2020 FY | -6.02 Million SEK | 86.18% |
| 2020 Q3 | -695 Thousand SEK | 59.14% |
| 2020 Q2 | -1.7 Million SEK | 34.68% |
| 2019 FY | -43.57 Million SEK | 11.23% |
| 2018 FY | -49.09 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 93.413% |
| Ziccum AB (publ) | -21.56 Million SEK | 23.929% |
| BioArctic AB (publ) | 252.64 Million SEK | 106.492% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -1840.947% |
| Mendus AB (publ) | -100.65 Million SEK | 83.705% |
| Genovis AB (publ.) | 54.22 Million SEK | 130.247% |
| Intervacc AB (publ) | -93.57 Million SEK | 82.474% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -5.731% |
| Active Biotech AB (publ) | -46.48 Million SEK | 64.717% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 191.071% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 70.404% |
| Aptahem AB (publ) | -10.1 Million SEK | -62.31% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 94.899% |
| Kancera AB (publ) | -65.04 Million SEK | 74.784% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 87.817% |
| Fluicell AB (publ) | -26.87 Million SEK | 38.982% |
| Saniona AB (publ) | -81.06 Million SEK | 79.768% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -32.576% |
| Biovica International AB (publ) | -126.07 Million SEK | 86.991% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 61.414% |
| AcouSort AB (publ) | -17.48 Million SEK | 6.21% |
| Xintela AB (publ) | -57.23 Million SEK | 71.346% |
| Abliva AB (publ) | -96.54 Million SEK | 83.013% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 94.95% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -367.932% |
| OncoZenge AB (publ) | -15.9 Million SEK | -3.138% |
| Amniotics AB (publ) | -29.07 Million SEK | 43.587% |
| 2cureX AB (publ) | -36.36 Million SEK | 54.896% |
| CombiGene AB (publ) | -36.3 Million SEK | 54.825% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -12.029% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 95.733% |
| Camurus AB (publ) | 532.35 Million SEK | 103.081% |
| Corline Biomedical AB | -1.78 Million SEK | -817.282% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 90.927% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 60.653% |
| I-Tech AB | 24.43 Million SEK | 167.121% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 97.92% |
| Cyxone AB (publ) | -21.66 Million SEK | 24.283% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 84.522% |
| Biosergen AB | -27.26 Million SEK | 39.846% |
| Cantargia AB (publ) | -290.01 Million SEK | 94.345% |
| NextCell Pharma AB | -43.17 Million SEK | 62.01% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 90.927% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | 4.067% |
| Nanologica AB (publ) | -69.96 Million SEK | 76.558% |
| SynAct Pharma AB | -224.49 Million SEK | 92.694% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 62.874% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | 31.532% |
| LIDDS AB (publ) | -40.67 Million SEK | 59.677% |
| Lipum AB (publ) | -37.25 Million SEK | 55.975% |
| BioInvent International AB (publ) | -369.94 Million SEK | 95.567% |
| Alzinova AB (publ) | -16.52 Million SEK | 0.732% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 93.529% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -156.536% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 85.747% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | 18.561% |
| Simris Alg AB (publ) | -36.63 Million SEK | 55.231% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 88.81% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 94.717% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 85.213% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -41.804% |